US Patent
US8987463 — Methods of synthesizing factor Xa inhibitors
Formulation · Assigned to Millennium Pharmaceuticals Inc · Expires 2030-12-28 · 5y remaining
Vulnerability score
48/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects methods for synthesizing betrixaban, a compound also known as Bevyxxa, and compositions comprising substantially pure betrixaban.
USPTO Abstract
Described herein are novel methods of preparing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the method is for preparing betrixaban or a pharmaceutically acceptable salt thereof. Also described are compositions comprising substantially pure betrixaban free base or salt thereof.
Drugs covered by this patent
- Bevyxxa (BETRIXABAN) · Portola Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.